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This journal is ª The Royal Society ofProtein free microcapsules obtained from plant spores
as a model for drug delivery: ibuprofen encapsulation,
release and taste masking
Alberto Diego-Taboada,ab Laurent Maillet,c Joseph H. Banoub,d Mark Lorch,c
Alan S. Rigby,a Andrew N. Boa,c Stephen L. Atkinab and Grahame Mackenzie*bc
Sporopollenin exine capsules (SEC) extracted from Lycopodium clavatum spores were shown to
encapsulate ibuprofen as a drug model, with 97  1% eﬃciency as measured by recovery of the loaded
drug and absence of the drug on the SEC surface by scanning electron microscopy (SEM). The
encapsulated ibuprofen was shown to be unchanged from its bulk crystalline form by solid state NMR,
FTIR and XRD. Essential for drug delivery applications, SEC were shown to be non-toxic to human
endothelial cells and free of allergenic protein epitopes by MALDI-TOF-MS and ESI-QqToF-MS. Potential
application for targeted release into the intestinal region of the gastrointestinal tract (GIT) was
demonstrated by 88  1% of the drug being retained in simulated gastric ﬂuid (SGF) after 45 minutes
and 85  2% being released after 5 min in buﬀer (PBS; pH 7.4). The SEC were shown to provide
signiﬁcant taste masking of encapsulated ibuprofen in a double blind trial with 10 human volunteers.Introduction
Drug delivery using microcapsules is becoming increasingly
important, endowing desirable features such as drug stability,
targeting and controlled release.1–4 Microcapsule manufacture
can be costly and diﬃcult, particularly to obtain microcapsules
with uniform morphology, size, chemical structure, and carrier
capacity, together with eﬃcient biodegradability and payload
release. Plant spores were chosen as the source for the micro-
capsules used for this study, since along with pollen they have a
number of identiable advantages over conventional materials;
however, materials from this source are oen associated with
the potential of being allergenic which is addressed in this
paper. Advantageously, microcapsules extracted from pollen
and spores are almost identical in size and morphology for a
given species, readily obtainable in large bulk quantities in
some cases, and renewable. A choice of size can be made from
5 mm (Myostis: forget-me-not) to 250 mm diameter (Cucurbita:
pumpkin) although only some species can be obtained
currently in quantities that would render them economically
viable in large amounts: examples are Lycopodium clavatum
spores and the pollen of Secale cereale and various species of
pine. Currently pollens and spores are marketed as herballl, Hull HU6 7RX, UK
YO25 6TX, UK
f Hull, Hull HU6 7RX, UK. E-mail:
66410; Tel: +44 (0)1482 465479
nch, N.A.F.C, P. O. BOX 5667, 80 East
Canada
Chemistry 2013remedies,5 nutraceuticals6,7 as well as being used in reworks.
The outer wall (the exine) of pollen and spores is constructed
primarily of the bio-polymer sporopollenin. In comparison to
other bio-polymers it is extraordinarily resistant to temperature,
pressure and most chemicals,8 with the exception of strong
oxidising. Such stability is reected in sporopollenin being the
sole bio-polymer to survive chemically and morphologically
intact aer millions of years in sedimentary rocks.9 Evacuation
of the protoplasmic contents of plant spores and pollen give
sporopollenin exine capsules (SEC). The protocols are simple
and use inexpensive, non-toxic agents such as strong mineral
acids and bases.8,10 SEC can also be obtained using a one-pot
procedure.11,12 The exact structure and biosynthesis of sporo-
pollenin are not fully understood, but it has been described as
an oxidative polymer of carotenoids13 or polyunsaturated fatty
acids.8,14–16 The high physical and chemical stability and
uniformity characteristics of SEC from L. clavatum have led to
their use as a solid phase support for peptide synthesis17,18 as a
ion-exchange resin19 and micro-reaction vessel.20 Particular
properties of SEC are their ability to readily microencapsulate a
wide range of materials with high loadings.10,21 Additional
properties of SEC include elasticity22 and permeability.23 The
latter is due to the many narrow (20–40 nm diameter) multi-
directional channels that penetrate the SEC giving passage to
actives in and out of the relatively large chamber within the SEC.
In addition, the morphology of the outer surface of SEC is
peculiar to individual plant species. This property has been of
use to forensic scientists24 over many years and may be impor-
tant in adhesion properties required of pollen during pollina-
tion. Therefore, it might be that the outer surface architecture ofJ. Mater. Chem. B, 2013, 1, 707–713 | 707
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View Article OnlineSEC, such as shown in Fig. 1, could play a role in mucosal
adhesion and assist in drug delivery properties.
The range of properties exhibited by SEC oﬀer the potential
for a wide range of applications in the eld of microencapsu-
lation including drug delivery.25,26Of particular note, it has been
shown that eicosapentaenoic acid (EPA) can be delivered into
the bloodstream of humans with a 10-fold increase in
bioavailability when administered orally as the ethyl ester
encapsulated into SEC obtained from L. clavatum.25
The morphology of pollen and spore shells including their
outer surfaces has been copied. Inorganic and polystyrene
replicas of spore exines have been synthesised27,28 as micro-
capsules (size range 10–15 mm) and shown, in in vitro studies,
that they can release encapsulated ibuprofen as the active
component into buﬀer solution.27,28 Perhaps surprisingly, this
property for this drug has not been demonstrated by the natural
sporopollenin microcapsule, SEC, and nor has the ability been
shown to model selective delivery to one part of gastrointestinal
tract (GIT). Furthermore, the natural SEC have been shown to
taste mask29 and partially degrade in human plasma30 but such
properties have not been reported for replicas of SEC.
Controlled release throughout the GIT using microcapsules
is attracting a variety of approaches currently using such as
sodium alginate hydrogels,31 pectin–casein complexes32 and
chitosan-denatured b-lactoglobin.33 In contrast to such mate-
rials, the sporopollenin of SEC is highly resilient to strong acid,
strong alkali and a large range of diﬀerent enzymes34,35 normally
found in the GIT. From an in vivo perspective, pollen exines
have been detected in human faeces in a number of studies.36,37
These reports are strongly in support of sporopollenin not being
biodegraded throughout digestion in the GIT. Our recent oral
drug delivery study, involving human volunteers, using SEC
obtained from L. clavatum spores25 showed that the majority
(circa 10-fold) of the drug (EPA) was released during passage
through the intestinal region of the GIT. Therefore it was ofFig. 1 Showing surface architecture of SEC encapsulated with ibuprofen (1 : 1,
w/w) but with no evidence of any solid deposits of ibuprofen.
708 | J. Mater. Chem. B, 2013, 1, 707–713interest to demonstrate the ability of an active to be released
from the SEC triggered by the pH conditions found in the GIT.
Ibuprofen was chosen as the active since it is conveniently
accessed, assayed28 and provides a comparative model with
other release studies performed using synthetic microcapsules
such as ethyl cellulose microspheres36 and in particular, inor-
ganic porous micron-sized particles made from silica, calcium
carbonate or calcium phosphate.27 However, before SEC can be
oﬀered as a microcapsule for oral drug delivery, important
factors that require addressing are the absence of allergenic
proteins and non-toxicity. An additional bonus for oral delivery
is the ability to taste mask. This study used SEC obtained from
L. clavatum spores since the spores are commercially available
and the SEC can be readily extracted by simple non-toxic
reagents.Results and discussion
Protein free and non-toxic SEC from L. clavatum spores
Exine preparation in this study employed a modication of the
method described by Zetsche and Vicari37 from L. clavatum
spores, which avoids the use of toxic reagents. Briey, hot
acetone was used initially to remove lipid followed by aqueous
potassium hydroxide to evacuate sporoplasmic contents. The
product obtained at this stage possesses two layers, an inner
wall (the intine) composed of polysaccharides and outer (the
exine) composed of sporopollenin. For this study the intine was
removed by harsh treatment with orthophosphoric acid to give
the nal sporopollenin exine microcapsules (SEC). Despite
robust processing, the SEC retains almost the same size and
morphology of the original spores harvested from the L. clav-
atum plant. The spores are commercial availability in large
quantities (e.g., Manoj Tibrewala, Nepal). They have a rounded
form of 25 mm with a relatively large single internal cavity as
depicted in an earlier study.21
As reported previously,10,21,38 SEC extracted from L. clavatum
spores have zero% N by combustion elemental analysis, which
is indicative of the absence of allergenic proteins on the surface
of SEC. However, legislative bodies such as the UK's Food
Standards Agency provide guidance39 on more accurate
methods to assure absence of allergenic protein residues in
food products. Electrophoresis is proposed, but of particular
note is the use of mass spectrometric (MS) techniques such as
MALDI-TOF-MS and ESI-QqToF-MS. Therefore, a series of
rigorous assays were repeated using sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and a variety of
MS techniques to detect trace amounts of proteins or peptides.
Initially, standard extraction procedures were followed that are
normally used for the disruption of cells.40 Thus, repeated
detergent-based lysis and corresponding sonication methods
were applied to six repeat extraction samples of SEC.41 Attempts
to detect the presence of proteins in the extracts by SDS-PAGE
and the traditional Lowry method proved unsuccessful with all
of the samples. In support of these observations none of the
extracts obtained from any of the six repeat extracted SEC
samples revealed the presence of protein by either electrospray
ionization with a hybrid QqTOF instrument (ESI-QqTOF-MS) orThis journal is ª The Royal Society of Chemistry 2013
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View Article OnlineMALDI-TOF/TOF-MS techniques in the positive ion mode.
Therefore it can be concluded that SEC extracted from L. clav-
atum by the method used in this study, are free of allergenic
protein, at least to the standards required by advisory bodies on
food legislation.39 Based on the study herein, it is plausible that
similar extraction methods might also generate sporopollenin
microcapsules that are free of allergenic proteins thus oﬀering
scope for a wider range of sporopollenin microcapsules avail-
able with diﬀerent sizes and morphologies to enlarge the range
of applications in such as drug delivery, food, beverages,
cosmetics and household products where the absence of
protein allergens is essential.Fig. 2 13C CP MAS NMR spectrum of (a) SEC, (b) SEC plus bulk ibuprofen, (c)
ibuprofen encapsulated within SEC and (d) bulk ibuprofen. Spectra were collected
at 20 C, with 8 kHz sample spinning. Peaks labelled with arrows indicate spinning
side bands.
Fig. 3 XRD of (A) SEC, (B) ibuprofen encapsulated within SEC and (C) bulk
ibuprofen.Encapsulation of ibuprofen into SEC and release of the drug
into simulated biological media
Encapsulation of a substance into SEC is perhaps more simple
than conventional means of microencapsulation, such as spray
drying. Diﬀerent methods have been reported to ll SEC with an
active;10,21 however, in this study an ethanolic solution of
ibuprofen was drawn into the SEC under vacuum to achieve a
loading of 1 : 1 w/w. The eﬃciency of loading was assessed by:
(i) assaying the amount ibuprofen extracted from the SEC into
ethanol; (ii) examination of the surface of the SEC for any
evidence of drug deposits. Thus 97  1% of ibuprofen was
recovered from the SEC and found to be identical with the
original drug without any additional peaks in the NMR or FTIR
spectra indicating the absence of degradation by-products or
contaminants extracted from the SEC. The drug loading of, 1 : 1
w/w (50% w/w) chosen for the study is at a competitive level with
other types of microencapsulation.42,43 At this loading and on
repeat runs, no evidence was observed, by scanning electron
microscopy, of ibuprofen precipitating on the surface of the SEC
(Fig. 1). A comparison of FTIR spectra of a ground mixture of
bulk ibuprofen and SEC (1 : 1 w/w) and the encapsulated
formulation showed no diﬀerence in wave numbers, suggesting
no morphological changes or no detectable interaction between
the two components. This was further supported by a similar
comparative study using solid state 13C CP MAS NMR involving
SEC alone, SEC plus bulk ibuprofen, ibuprofen encapsulated
within SEC and bulk ibuprofen indicating that the bulk
ibuprofen is unaltered in the encapsulated form (Fig. 2).
Conrmation of encapsulated ibuprofen being in its crys-
talline form comparable with its bulk form was evident from a
similar comparative study using XRD (Fig. 3). This result is in
contrast to such as ibuprofen encapsulated into meso-struc-
tured silica which was found by XRD to be amorphous.44
Release of ibuprofen into agitated environments of excess
simulated gastric uid (SGF) and phosphate buﬀer was followed
over 45 minutes (Fig. 4; Table 1). To maintain comparability
with release into eachmedium, each time point was achieved by
a separate experiment in which the loaded SEC were charged to
a fresh medium and assayed by determining the ibuprofen
remaining in the SEC by extracting into ethanol. In SGF, the
release prole formed a plateau aer 5–10 min which was
maintained over the duration (45 min) of the study, with an
overall loss of some 12 1% of the drug from themicrocapsulesThis journal is ª The Royal Society of Chemistry 2013indicating the feasibility of the SEC to a retain the majority
(88  1%) of the drug during transit through the stomach. In
contrast when SEC at the same loading level of the drug, were
agitated in an excess of phosphate buﬀer (pH 7.4) to mimic the
change from the gastric environment, most (85  2%) of the
payload was released aer 5 min. This comparative release
study is indicative of suitably loaded SEC, with either active or
excipient, being able to release the payload in accordance with
the diﬀerent pH conditions such as found in the GIT. It is of
note that the morphology of SEC remained unchanged as
viewed by SEM following exposure to SGF and PBS over
1 month.
Toxicity testing of SEC
Whilst pollen and plant spores are found in many foods and
have been used as foods and medicines4 only little data has
been published on toxicological assessment of sporopollenin in
which sporopollenin from Chlorella vulgaris was fed in large
quantities to rats with no ill eﬀect.45 However, no assessments
have been made with well recognised in vitro tests such as
toxicity to human endothelial cells.46 Therefore SEC wereJ. Mater. Chem. B, 2013, 1, 707–713 | 709
Table 1 Release of drug from ibuprofen loaded SEC (1 : 1 w/w) over time
Time (s)
% of ibuprofen released
SGF PBS
5.0 8.0  1.6 84.8  2.2
15.0 10.0  1.4 88.0  2.0
30.0 12.1  1.9 89.5  1.2
45.0 12.2  1.1 93.0  2.1
Fig. 4 Release of ibuprofen from SEC into simulated gastric ﬂuid (SGF) and
phosphate buﬀer (PBS) to mimic intestinal ﬂuid.
Journal of Materials Chemistry B Paper
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View Article Onlineexposed to two types of cells, namely human umbilical vein
endothelial cells (HUVEC), which are endothelial cells extracted
from the vein of an umbilical cord of the immortalised endo-
thelial cell line EAhy 926. Four diﬀerent assays were used to
assess the eﬀects of the SEC on endothelial cells: (i) WST-1
proliferation assay; (ii) cell death ELISA for apoptosis; (iii) LDH
assay for necrosis; (iv) microscopic examination of the cells to
look for cell damage and apoptotic bodies. All of the tests
undertaken showed that SEC did not reduce the proliferation or
induce cell death in human endothelial cells in vitro at
concentrations between 100ng and 10ug. Furthermore, no cell
damage was observed by SEM within this concentration range.Table 2 Double blind taste trial involving 10 volunteers comparing:a bulk
ibuprofen with SEC;b bulk ibuprofen with ibuprofen encapsulated into SEC in the
ratio 1 : 1 w/w;c SEC with ibuprofen encapsulated into SEC in the ratio 1 : 1 w/w
Time 2
Time 1
Taste same Taste diﬀerent Total pairs
Taste same 1a, 6b, 6c 3a, 5b, 3c 4a, 5b, 9c
Taste diﬀerent 2a, 1b, 1c 4a, 4b, 0c 6a, 5b, 1c
Total pairs 3a, 1b, 7c 7a, 9b, 3c 10a, 10b, 10c
a p-Value ¼ 0.10; discordant odds ratio ¼ 3 : 2. b p-Value ¼ 0.10;
discordant odds ratio ¼ 5 : 1. c p-Value ¼ 0.10; discordant odds
ratio ¼ 3 : 1.Taste masking of ibuprofen by SEC
In keeping with the perspective of using SEC for oral delivery, a
limited taste trial was undertaken using human volunteers. A
comparison was made by administering powders to the tongues
of the volunteers of ibuprofen alone, as a mixture with SEC and
encapsulated into SEC. We have reported earlier that SEC
obtained from L. clavatum exhibit taste masking properties for
sh oils which are unpalatable to some people.29 However,
ibuprofen is solid at room temperature and has a distinctly
diﬀerent taste to sh oil. It has a strong, astringent and bitter
taste that is normally masked to make it easier to ingest.47 It is
of note that human taste discrimination is highly evolved: there
are 25 putatively bitter taste receptor genes coding for G protein-
coupled receptors, referred to as the T2T family that can
distinguish bitter stimuli and pungent compounds at low
thresholds.48 With such high sensitivity it seemed that a taste
masking study could reect on the eﬃciency of encapsulation to
give an indication of whether such a formulation may have710 | J. Mater. Chem. B, 2013, 1, 707–713viability for oral delivery without any additional excipient.
Powdered drugs are a useful dosing form for patients who may
experience diﬃculty in swallowing tablets or capsules. In
addition, the development of medicines that are easier to ingest
has attracted special interest from the viewpoints of treatment
compliance and marketability.49 Other microspheres as
powders have been developed for taste masking to protect the
bitter tasting drugs from coming in to contact with the patients'
taste buds.50 The double blind taste masking study reported
herein (Table 2) was conducted with 10 human volunteers to
compare, at randomized time points, the ne powders: bulk
ibuprofen with SEC; bulk ibuprofen with ibuprofen encapsu-
lated into SEC in the ratio 1 : 1 w/w; SEC with ibuprofen
encapsulated into SEC in the ratio 1 : 1 w/w. This albeit limited
study showed some clear distinctions. It was found that there
was a signicant chance that volunteers could distinguish
between ibuprofen and empty SEC with a discordance ratio of
3 : 2. Also, the chance of a volunteer nding the same taste
between SEC alone with ibuprofen encapsulated into SEC was
marked with a discordant ratio of 3 : 1. However, most strik-
ingly was that volunteers were 5 times (discordance ration of
5 : 1) more likely to detect a diﬀerence between ibuprofen alone
and the ibuprofen encapsulated into SEC formulation. These
data indicate that SEC oﬀer a signicant degree of taste mask-
ing which perhaps reects that only a small proportion of the
loaded ibuprofen emerges as being detectable, by taste, on the
surface of the SEC.Experimental
Materials
Lycopodium clavatum (common club moss) spores (27 mm type)
were purchased from Tibrewala International (Kathmandu,
Nepal). Chemicals used were purchased from Sigma-Aldrich, or
Fisher. Sporopollenin exine capsules (SEC) were prepared
according the procedure reported previously. Ibuprofen was
purchased from Acros. SGF was freshly prepared containing
NaCl (2 g l1) and having a pH of 1.5 adjusted with HCl 2 M.51General experimental procedures
All NMR experiments were carried out at 20 C on a Bruker
Avance II 500 MHz spectrometer using a 4 mm magic angleThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlinespinning (MAS) probe operating at 125.7546 MHz for 13C
measurements. Spectra were externally referenced to tetrame-
thylsilane at 0 ppm. Experiments were carried out with 8 kHz
sample spinning. Spectra were collected using cross polariza-
tion (CP) and TPPM decoupling during the acquisition period of
30 ms. All NMR data were processed using ‘Topspin’ Version 1.3
(Bruker Instruments, Karlsruhe, Germany). 100 mg of SEC or
ibuprofen encapsulated into SEC or bulk ibuprofen was packed
into 4 mm MAS rotors, accordingly. Scanning electron micro-
graphs were obtained using a Leica Cambridge Stereoscan 360
Scanning Electron Microscope. Samples were mounted on a
metal stub with an adhesive and coated under vacuum with
carbon before being coated with 200 A˚ gold lm. API-QSTAR XL
QqTOF-MS/MS hybrid tandem mass spectrometer used an
Applied Biosystems International-MDS Sciex, Foster City, CA,
USA equipped with a nano-electrospray source (Protana XYZ
manipulator) which produces the electrospray through a Pico-
Tip needle (10 mm i.d., New Objectives, Wobum, MA, USA)
carrying a voltage of 2400 V. The samples were introduced by
direct injection in an acetonitrile : water (3 : 1) solvent. The
mass spectra were acquired from m/z 100 to m/z 2000. MALDI-
TOF-MS analysis was carried out on a 4700 Proteomics analyzer
with TOF-TOF optics (Applied Biosystems Foster City, CA, USA)
and a 200 Hz 10 frequency-tripled Nd:YAG laser.a-cyano-4-
hydroxycinnamic acid (a-CHCA) was used as matrix for the
analysis of the so-called protein extract with an average of 5000
to 8000 laser shots per spectra. X-ray diﬀraction measurements
were made using a PANalytical CubiX PRO diﬀractometer
(Amelo, Netherlands) at a wavelength of 1.5418 A˚ generated by a
copper long-ne focus tube operated at 45 kV and 40 mA.
Samples were mounted on a silicon wafer mount and analysed
in reection geometry in q–2q conguration over the scan range
2 to 40 2q with 1.905 seconds exposure per 0.0025067
increment.
Encapsulation of ibuprofen into SEC
A solution of ibuprofen (1.03 g) in ethanol (1 cm3) was added to
SEC (1.10 g) with gentle stirring and vortexed for 1 min. to
obtain a homogeneous mixture, which was subjected to a
vacuum (ca. 10 hPa) for 1.5 h. The sample was freeze dried to a
constant weight.
Loading eﬃciency and in vitro release into simulated gastric
uid and phosphate buﬀer
Ibuprofen was assayed in accordance with a published method
using UV-vis spectroscopy.52 Calibration were made using
standard solutions of ibuprofen in ethanol over the concen-
tration range 16.5–404.0 mg cm3 by plotting absorbance of
ibuprofen (A) obtained by UV-vis spectroscopy at 238 nm versus
ibuprofen concentration [c]. The ibuprofen samples were
prepared in six diﬀerent concentrations. Linear regression
analysis of A versus [c] was attained using Microso Excel and
gave the equation A ¼ 0.0032[c] + 0.0168. The loading eﬃciency
was determined by stirring the ibuprofen loaded SEC (20 mg) in
ethanol (10 cm3) for 10 min aer which the SEC were removed
by ltration (porosity grade 3). This operation was repeatedThis journal is ª The Royal Society of Chemistry 2013twice, the ltrate was diluted up to 50 cm3 and the loading
eﬃciency of ibuprofen calculated to be 97  1%.
For drug release studies, the drug-loaded SEC (1 : 1 w/w)
(0.02 g) were stirred in simulated gastric uid (10 cm3) pH 1.5
and phosphate buﬀer saline (10 cm3) pH 7.4, respectively. Aer
the prescribed period Table 2; Fig. 4, the suspension was
ltered. The remaining ibuprofen was extracted from the exines
into ethanol (10 mL) and ltered. Each operation was repeated
twice and the ltrate was diluted up to 50 cm3 and the amount
of ibuprofen remaining determined by UV-vis spectroscopy.
Percentage data are based on 100% being the initial loading of
ibuprofen.Taste trial
Ten volunteers participated in the taste trial. The tasters had not
been trained and were blinded during the test. The samples
consisted of SEC loaded with ibuprofen (1 : 1 w/w), empty SEC
and bulk ibuprofen alone. The volunteers were informed that
the samples possibly contained ibuprofen, ibuprofen and SEC
or simply SEC. Each one of the ten volunteers tasted, in a
random order, ca. 20 mg of 6 lots of paired samples, using a
clean plastic straw to deliver the sample directly to the tongue.
Samples were given as follows: 2 samples of each of bulk
ibuprofen, empty SEC and ibuprofen loaded SEC for control.
Subsequently, each volunteer tasted a sample of bulk ibuprofen
and a sample of empty SEC; a sample of ibuprofen and
ibuprofen loaded SEC; a sample of empty SEC and a sample of
ibuprofen loaded SEC. Between each sample tasting, the
volunteers rinsed their mouths thoroughly with water. Samples
were assessed throughout the process, with volunteers
attempting to identify if the samples were the same or diﬀerent.
Pairs of samples were marked with a one if the volunteers
thought that they were the same and marked with a zero if they
thought that the paired samples were diﬀerent. Thus there were
three experiments carried out at two time-points by each of 10
observers as described previously. There were no missing data.
The results of the rst set of experiments are presented as
frequencies only. By combining data from both time points we
calculated between observer reliability. Thus, three separate 2
2 tables, were generated representing matched pairs, combined
as Table 2.53 Discordant (for taste) pairs are shown in Table 2 on
the top right hand cell and bottom le hand cell respectively,
concordant (for taste) otherwise. Although this was not a pow-
ered study p-values were calculated using McNemar's test.47Analysis of SEC extracts using electrophoresis and mass
spectrometry
DETERGENT-BASED LYSIS PROTEIN EXTRACTION OF SEC. SEC (1 g) were
extractedusing ice-cold buﬀer containing 50mMsodiumacetate
(pH 5.2), (100 cm3) 1 mM ascorbic acid, 0.5 mM phenyl-
methylsulfonyl uoride and 0.5% polyvinyl polypyrrolidone.
Subsequent to centrifugation, the supernatant was precipitated
with 30%ammoniumsulphate, at 4 C, overnight. The pellet was
discarded and the supernatant was desalted using a Sephadex G-
50 column and the eluent (acetonitrile–water) was evaporated:J. Mater. Chem. B, 2013, 1, 707–713 | 711
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View Article Onlinethe residue was dissolved in water, lyophilized and used for
protein identication.40
SONICATION LYSIS PROTEIN EXTRACTION OF SPOROPOLLENIN. The
protocol followed was in accordance with that report by Brug-
geman and Westerhoﬀ41 SEC (100 mg) were pulverized in
liquid nitrogen using a mortar and pestle, sonicated in tri-
chloroacetic acid : acetone (1 : 9 w/v) solution in a sonic water
bath. The SEC were washed successively with methanol (3 
100 cm3), acetone (3  100 cm3), and phenol (3  50 cm3). The
addition of excess ammonium acetate–methanol failed to give
precipitate.
ELECTROPHORETIC SEPARATION OF PROTEINS. Attempts to detect
proteins in SEC extracts were made using sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) at
diﬀerent acrylamide/bisacrylamide concentrations (12%
resolving/4% stacking gels) using a vertical slab gel electro-
phoresis apparatus. Each lane received 50 mL of the SEC extract.
Electrophoresis was conducted at 50–100 V. No proteins were
detected in the gels by staining with coomassie brilliant blue
R250 for 2 to 4 hours.
ESI-QQTOF-MS AND CID-MS/MS ANALYSIS. A solution of aceto-
nitrile : water (7 : 3) and SEC extracts was injected directly into
the ESI source of an ESI-QqTOF-MS recorded in the positive ion
mode. Neither single fragment ions nor multi-charged ions
were noted in the ESI-MS, from any of the six repeated extrac-
tion preparations; hence it was concluded that none of the SEC
extracts contained any protein or peptide.
MALDI-TOF-MS ANALYSIS. MALDI-TOF-MS analysis of the SEC
extracts used a YAG laser.a-cyano-4-hydroxycinnamic acid
(a-CHCA) as matrix with an average of 5000 to 8000 laser shots
per spectra. 1 mL of a 20 mg mL1 solution of a-CHCA (dis-
solved in acetone) and 0.1% triuoroacetic acid (TFA) was
spotted on the MALDI plate and dried at room temperature (the
use of acetone allowed good homogeneity of the matrix). Then,
an aliquot of 1 mL of each SEC extract was spotted on the top of
the dried matrix and le to dry before the MALDI-MS experi-
ments. The analysis was achieved in the linear mode and the
MALDI-TOF mass spectrometer was calibrated using BSA.
Neither peptide nor protein was detected in any of the repeat
extracted SEC extractions.Toxicity testing using human umbilical vein endothelial cells
(HUVEC) and an endothelial cell line EAhy 926
EFFECTS OF SEC ON HUVEC PROLIFERATION. HUVECs (25 000 per
well 12 well plate) (2500 per well 96 well plate) were allowed to
adhere to cell culture plates for two hours before SEC (1 ng
mL1 to 10 mg mL1) (diluted in culture media) were added.
Aer two days the eﬀects of the SEC were assessed microscop-
ically (12 well plate) and for proliferation by WST-1 (96 well
plate). To avoid any problems with the SEC aﬀecting the
absorbance readings which are an integral part of the WST-1,
the plate for the WST-1 assay was washed with PBS and fresh
growth media was added to remove the SEC prior to starting the
3 h. Photomicrographs of HUVE cells treated with the SEC
showed no sign of any cellular damage at the concentrations712 | J. Mater. Chem. B, 2013, 1, 707–713100 ng to 10 mg. In addition the SEC did not reduce proliferation
of the HUVEC when compared to the untreated control.
EFFECTS OF SEC ON EAHY 926 CELLS. EAhy 926 cells (25 000 per
well 12 well plate) (2500 per well 96 well plate) were allowed to
adhere to cell culture plates overnight before spores (1 ng mL1
to 10 mg mL1) (diluted inmedia) were added. Aer two days the
eﬀects of the SEC were assessed microscopically (12 well plate)
and for proliferation byWST-1 (96 well plate). A further two days
later cell death in the samples was assessed using the cell death
ELISA for apoptosis and LDH for necrosis assays. To avoid any
problems with the SEC aﬀecting the absorbance readings which
are an integral part of the WST-1, the plate for the WST-1 assay
was washed with PBS and fresh growth media was added to
remove the SEC prior to starting the 3 h. It was found that SEC at
concentrations 100 ng to 10 mg did not reduce proliferation of
EAhy 926 cells when compared to the untreated control and did
not increase the amount of cell death.Conclusion
Ibuprofen can be encapsulated into SEC eﬃciently (97 1%) by
a simple and rapid method to generate uniform microcapsules
with a loading of 1 : 1 w/w, which have a surface free of the drug
as detected by SEM. Solid state NMR, FTIR and XRD measure-
ments are consistent with ibuprofen being encapsulated as in
its bulk crystalline form. Release proles of encapsulated
ibuprofen into simulated gastric and intestinal uids respec-
tively, indicate that an encapsulated material can be released
rapidly in high yield from SEC triggered by pH. This observation
is perhaps a model for other actives or excipients which might
be released in a similar manner. Importantly, exhaustive ana-
lysis of extracts of the SEC revealed no protein content by mass
spectrometric methods approved by food advisory bodies. In
addition, SEC were shown not to reduce the proliferation or
induce cell death in human endothelial cells in vitro at
concentrations between 100 ng and 10 mg. The SEC were shown
to mask the taste of the bitter tasting ibuprofen when encap-
sulated suggesting a low drug availability on the surface of the
SEC and the potential for use of SEC in powdered drug
formulations for oral dosing. The evidence presented herein
point to SEC having a potential for safe application to such as
drug delivery and other areas such as food, cosmetics and
beverages.Acknowledgements
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